KEVIN CLEARMAN: Open Payments
NPI 1477557098 · HATTIESBURG, MS. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,308 in 80 payments from 16 companies in 2025. Trend: 2023 $1,732 · 2024 $1,412 · 2025 $1,308
Food & beverage: $1,308
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 21 | $247 |
| AstraZeneca Pharmaceuticals LP | 8 | $233 |
| Novo Nordisk Inc | 19 | $213 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 7 | $151 |
| Exact Sciences Corporation | 4 | $97 |
| Amgen Inc. | 4 | $62 |
| Lilly USA, LLC | 3 | $55 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $46 |
| Lundbeck LLC | 2 | $40 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $37 |
Products named: XIFAXAN, FARXIGA, VRAYLAR, QULIPTA, AIRSUPRA, Ozempic, The Cologuard Plus Collection Kit, Rybelsus.
Industry payments across MS — which companies pay providers there.
